SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
PLANO, Texas, Feb. 06, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & Chief Financial Officer, are scheduled to conduct a fireside chat presentation at the Leerink Partners 6th Annual Global Healthcare Conference in New York, NY. Management will also be available for one-on-one meetings at the conference.
| Event: | Leerink 6th Annual Global Healthcare Conference |
| Format: | Fireside Chat and One-on-One Meetings |
| Date: | Thursday, February 16, 2017 |
| Time: | 11:00 am ET |
A webcast of the Company’s fireside chat will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com. A webcast replay of the chat will be available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
